
Embracing the Change: 2020 China NRDL Outlook
China’s 2020 NRDL (National Reimbursement Drug List) process has been unfolding since July this year with a number of new changes and interesting twists. Based on Simon-Kucher’s extensive experience and observations, as well as ongoing discussions with key players and stakeholders in the industry, we have identified three themes and made five predictions on the likely outcomes of 2020 NRDL process.
China’s NRDL (National Reimbursement Drug List) updates and negotiations have become one of the most watched events in recent years, and for good reasons. First of all, they directly affect all the industry players in the world’s second largest pharma market, including multinational pharma majors, biotech, and Chinese companies alike. Second, the results have real-life impacts and implications on the entire Chinese population, as access to and coverage of the right drugs could make a world of difference for the patients in need. Last but not least, there has been…

